hyperbilirubinemia

[키워드] 1:1 ACHE Acute coronary syndrome Acute kidney injury acute renal failure adequate hydration adjuvant therapy Admission allergy ALT/AST Altered mental status Anti-inflammatory anticoagulation antipyretics Antithrombotic approved ARDS Aspirin AST/ALT atorvastatin bleeding Blinding block randomization Breastfeeding brown urine change characterized clinical clinical feature Clinical features Coagulopathy college Combination comorbid condition comorbid conditions comparator conducted control group coronary syndrome Corticosteroid Corticosteroids cough COVID-19 CPK creatine creatine kinase creatinine CRP current therapy Dexamethasone dissemination dose drug dysfunction Dyspnoea dysregulation effective Efficacy and safety element Endothelial dysfunction enrolled ethical committee evaluate excluded ferritin Fever followed by greater heparin hepatotoxicity Hospital admission hospital discharge Hospital mortality Hospital stay hospitalised patient Hospitalised patients hyperbilirubinemia hypoxia ICMR IEC immune dysregulation immunomodulatory impaired consciousness in-hospital mortality India Inflammation Inflammatory marker inflammatory markers Intervention intervention group intolerance intravenous Intravenous remdesivir invasive limit liver low molecular weight low molecular weight heparin management marker mechanical ventilation medication medications moderate muscle ache myalgia Myoglobin Myopathy myositis national guidelines Nicorandil Non-invasive number objective once daily Open-label open-label trial outcome oxygen Oxygen requirement oxygen support participant pathophysiologic pathophysiology Patient Platelet Platelet count Pneumonia positive Pregnancy Primary outcome progression protocol raised Rajendra Prasad Randomised control trial randomization randomize Randomized Randomized controlled trial randomly divided receive recruitment reducing mortality Registered registry Remdesivir renal failure reported respiratory rate rhabdomyolysis room air RT-PCR safety endpoint safety endpoints Sample size SARS-CoV-2 infected patient SARS-COV-2 infection Schematic screened Secondary outcomes Sepsis serum serum markers severe disease Shock significant interaction SpO2 Standard Standard of care starting dose statin statins Study design Study protocol substrates supplementary material Symptom Symptomatic treatment Tablet therapeutic therapeutic agent therapy thrombocytopenia Treatment Trial Trial registration two-arm parallel ULN Urine weakness website
[DOI] 10.1186/s13063-021-05361-y PMC 바로가기 [Article Type] Letter